I am a principal investigator currently working at the University of Cologne. Our goal is to contribute to better outcomes for cancer patients by focusing our research efforts in two main areas. We develop novel immunotherapeutic approaches in hematological cancers and solid tumors and we use liquid biopsies to understand the cancer genome and measure treatment response in cancer patients at high resolution.In 2021 I founded Liqomics, an academic spin-off company aiming to bring liquid biopsy and minimal residual disease diagnostics to all patients and all cancers.I look forward to connect to people here on LinkedIn who are interested in academic and commercial collaboration.